Erste Group Bank AG (EBS) Earnings Call Transcripts
Erste Group Bank AG's Latest Earnings Call - June 8, 2026
Emergent BioSolutions Inc. reported its Q1 2026 earnings, highlighting a strong quarter that exceeded internal expectations for both revenue and EBITDA. Revenue was reported at $156 million, and EBITDA at $36 million, despite a slight decline from the previous year due to a non-recurring order in Q1 2025. The company improved its cash balance to $160 million, up $11 million from last year, and continued to focus on debt reduction and share repurchase programs. Management emphasized the multiyear turnaround plan, which has transitioned from stabilization to growth investment, particularly in products like TEMBEXA, raxibacumab, and Ebanga. Guidance was not explicitly changed, but the focus on international expansion and new product development was reiterated.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $156 million (beat) |
| EBITDA | $36 million (beat) |
| Cash Balance | $160 million (positive) |
| Net Debt Reduction | $122 million (positive) |
| Leverage Ratio | 2.4x (positive) |
Guidance from management
Management did not explicitly change guidance but emphasized ongoing investment in product development and international expansion as key growth drivers.
What analysts pressed on
Analysts expressed concerns about the sustainability of revenue growth given the reliance on government contracts and the potential impact of geopolitical shifts. Questions also arose regarding the competitive landscape for NARCAN and the company's ability to maintain market leadership.
Main topics on the call
- Revenue and EBITDA Performance — Emergent reported Q1 2026 revenue of $156 million and EBITDA of $36 million, both exceeding internal expectations. This performance was despite a slight year-over-year decline due to a one-time order in Q1 2025. "It was ...
- Debt Reduction and Cash Flow — The company reduced its net debt by $122 million and improved its cash balance by $11 million. Leverage decreased from 2.7x to 2.4x year-over-year, indicating a stronger financial position. "Debt reduction is down $110 m...
- Product Innovation and Development — Emergent introduced new innovations for NARCAN, including a carrying case and multipacks, to enhance accessibility. The company is also investing in new products like TEMBEXA, raxibacumab, and Ebanga, targeting growth in...
- International Expansion — International revenue diversification increased to 37% of total sales, up from 15% historically. This shift underscores a strategic focus on global market penetration. "We in the first quarter of 2026, have about 37% of ...
Read the full Erste Group Bank AG transcript (June 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Erste Group Bank AG
Erste Group Bank AG (EBS) is a publicly listed company in the Banks industry, within the Financials sector. It trades on WBAG and is based in AT. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 77 calls on record spanning January 14, 2020 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 77 Erste Group Bank AG earnings call transcripts on record, spanning January 14, 2020 to July 30, 2026. Based on this history, Erste Group Bank AG reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- EBS
- Exchange
- WBAG
- Country
- AT
- Sector
- Financials
- Industry
- Banks
- Calls on record
- 77
- First call
- January 14, 2020
- Most recent
- July 30, 2026
- Reporting cadence
- quarterly